CV Therapeutics, Inc. (NASDAQ:CVTX.DL)
CAPS Rating:
A biopharmaceutical company focused on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases.
A biopharmaceutical company focused on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases.
Recs
Will drift down/sideways for a month or so as buyout-hopeful buyers realize it won't sell to Astrella. Buy around 13 or even 14.
I usually dislike large jumps in one day.Acceptable short.